[go: up one dir, main page]

ES2422284T3 - Derivado de indol que tiene actividad inhibidora de cPLA2, uso del mismo y método para producirlo - Google Patents

Derivado de indol que tiene actividad inhibidora de cPLA2, uso del mismo y método para producirlo

Info

Publication number
ES2422284T3
ES2422284T3 ES08739849T ES08739849T ES2422284T3 ES 2422284 T3 ES2422284 T3 ES 2422284T3 ES 08739849 T ES08739849 T ES 08739849T ES 08739849 T ES08739849 T ES 08739849T ES 2422284 T3 ES2422284 T3 ES 2422284T3
Authority
ES
Spain
Prior art keywords
substituted
unsubstituted
halogen atoms
atoms
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08739849T
Other languages
English (en)
Inventor
Toshiyuki Tomoo
Takashi Nakatsuka
Yasuhiro Hayashi
Toyoko Katayama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Application granted granted Critical
Publication of ES2422284T3 publication Critical patent/ES2422284T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Un compuesto, o una sal del mismo, o un solvato del mismo, representado por la Fórmula (I): en donde R1 indica (1) un grupo hidrocarbilo aromático C6 a C14, (2) un grupo heterocíclico aromático de 5 a 10miembros que incluye de uno a cuatro heteroátomos seleccionados de átomos de nitrógeno, átomos de azufre yátomos de oxigeno, átomos distintos de carbono o (3) un grupo policíclico condensado bicíclico o tricíclico formadopor la condensación del grupo heterocíclico aromático arriba mencionado y el anillo cíclico de hidrocarbilo aromáticoC6 a C14 arriba mencionado, en donde dichos grupos (1) a (3) de R1 pueden estar opcionalmente sustituidos con uno a cinco gruposseleccionados de (i) un átomo de halógeno, (ii) un nitro, (iii) un ciano, (iv) un alquilo C1 a C6 no sustituido o sustituidocon uno a tres grupos seleccionados de un átomo de halógeno, un alcoxi C1 a C6 no sustituido o sustituido con uno atres átomos de halógeno, un aciloxi C1 a C7, un hidroxilo, un heterociclilo de 5 a 6 miembros no sustituido osustituido con 1 a 3 átomos de halógeno, un heterocicliloxi de 5 a 6 miembros no sustituido o sustituido con 1 a 3átomos de halógeno, un hidrocarbilo aromático C6 a C14 no sustituido o sustituido con uno a tres átomos dehalógeno, y un hidrocarbiloxi aromático C6 a C14 no sustituido o sustituido con uno a tres átomos de halógeno, (v) unalquenilo C2 a C6 no sustituido o sustituido con uno a tres átomos de halógeno, (vi) un alquinilo C2 a C6 no sustituidoo sustituido con uno a tres átomos de halógeno, (vii) un cicloalquilo C3 a C6, (viii) un hidroxilo (ix) un alcoxi C1 a C6 nosustituido o sustituido con uno a tres grupos seleccionados de átomo de halógeno, alcoxi C1 a C6 no sustituido osustituido con uno a tres átomos de halógeno, aralquiloxi C7 a C16, un hidroxilo, mono- o dialquilamino C1 a C6,carbamoilo, mono- o di-alquilcarbamoilo C1 a C6, mono- o di-aralquilcarbamoilo C7 a C16, carboxilo, alcoxicarboniloC1 a C6, aciloxi C1 a C6, un heterociclilo de 5 a 6 miembros no sustituido o sustituido con uno a tres átomos dehalógeno, un heterocicliloxi de 5 a 6 miembros no sustituido o sustituido con uno a tres átomos de halógeno, unhidrocarbilo aromático C6 a C14 no sustituido o sustituido con uno a tres átomos de halógeno, y un hidrocarbiloxiaromático C6 a C14 no sustituido o sustituido con uno a tres átomos de halógeno, (x) un hidrocarbiloxi aromático C6 aC14 no sustituido o sustituido con uno a tres grupos seleccionados de un átomo de halógeno, un alquilo C1 a C6, unalcoxi C1 a C6 y un hidroxilo, (xi) un heterocicliloxi de 5 a 6 miembros no sustituido o sustituido con uno a tres átomosde halógeno, (xii) un alquilendioxi C1 a C5, (xiii) un alquiltio C1 a C6 no sustituido o sustituido con uno a tres gruposseleccionados de un átomo de halógeno, un alcoxi C1 a C6, un hidroxilo, un mono- o dialquilamino C1 a C6, uncarbamoilo, un mono- o dialquilcarbamoilo C1 a C6, un mono- o diaralquilcarbamoilo C7 a C16, un carboxilo, unalcoxicarbonilo C1 a C6, un aciloxi C1 a C6, un heterociclilo de 5 a 6 miembros no sustituido o sustituido con uno atres átomos de halógeno, un heterocicliloxi de 5 a 6 miembros no sustituido o sustituido con uno a tres átomos dehalógeno, un hidrocarbilo aromático C6 a C14 no sustituido o sustituido con uno a tres átomos de halógeno y unhidrocarbiloxi aromático C6 a C14 no sustituido o sustituido con uno a tres átomos de halógeno, (xiv) un heterocicliltiode 5 a 6 miembros no sustituido o sustituido con uno a tres átomos de halógeno, (xv) un amino, (xvi) unmonoalquilamino C1 a C6, (xvii) un dialquilamino C1 a C6, (xviii) un amino cíclico de 5 a 6 miembros, (xix) un acilo C1a C6, (xx) un carboxilo, (xxi) un alcoxicarbonilo de C1 a C6, (xxii) un carbamoilo, (xxiii) un tiocarbamoilo, (xxiv) unmonoalquilcarbamoilo C1 a C6, (xxv) un dialquilcarbamoilo C1 a C6, (xxvi) un carbonilo heterocíclico de 5 a 6miembros no sustituido o sustituido con uno a tres átomos de halógeno, (xxvii) un sulfo, (xxviii) un alquil sulfonilo C1a C6, (xxix) un acilamino C1 a C6 no sustituido o sustituido con un alcoxi C1 a C6, (xxx) un alcoxicarbonilamino C1 a40 C6, (xxxi) un aminosulfonilo, (xxxii) un mono- o dialquilaminosulfonilo C1 a C6 y (xxxiii) un heterociclilsulfonilo de 5 a 6miembros no sustituido o sustituido con uno a tres átomos de halógeno.
ES08739849T 2007-03-29 2008-03-28 Derivado de indol que tiene actividad inhibidora de cPLA2, uso del mismo y método para producirlo Active ES2422284T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007088307 2007-03-29
JP2007156198 2007-06-13
PCT/JP2008/056742 WO2008120818A1 (ja) 2007-03-29 2008-03-28 ｃＰＬＡ２阻害活性を有するインドール誘導体およびその用途並びに製造方法

Publications (1)

Publication Number Publication Date
ES2422284T3 true ES2422284T3 (es) 2013-09-10

Family

ID=39808398

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08739849T Active ES2422284T3 (es) 2007-03-29 2008-03-28 Derivado de indol que tiene actividad inhibidora de cPLA2, uso del mismo y método para producirlo

Country Status (12)

Country Link
US (1) US8293781B2 (es)
EP (1) EP2141148B1 (es)
JP (1) JP5164972B2 (es)
KR (1) KR20090125799A (es)
CN (1) CN101679248A (es)
AU (1) AU2008233553A1 (es)
BR (1) BRPI0809542A8 (es)
CA (1) CA2681979A1 (es)
ES (1) ES2422284T3 (es)
MX (1) MX2009010302A (es)
RU (1) RU2009139931A (es)
WO (1) WO2008120818A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010149685A1 (en) 2009-06-24 2010-12-29 Boehringer Ingelheim International Gmbh New compounds, pharmaceutical composition and methods relating thereto
AU2010264720A1 (en) 2009-06-24 2011-12-08 Boehringer Ingelheim International Gmbh New compounds, pharmaceutical composition and methods relating thereto
TW201107315A (en) * 2009-07-27 2011-03-01 Kissei Pharmaceutical Indole derivatives, or the pharmaceutically acceptable salts
KR20120117905A (ko) 2010-01-28 2012-10-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 프로테아좀 활성을 향상시키는 조성물 및 방법
TWI429628B (zh) * 2010-03-29 2014-03-11 Univ Taipei Medical 吲哚基或吲哚啉基羥肟酸化合物
WO2011158108A2 (en) 2010-06-16 2011-12-22 Purdue Pharma L.P. Aryl substituted indoles and the use thereof
PT2707101T (pt) 2011-05-12 2019-05-30 Proteostasis Therapeutics Inc Reguladores da proteostase
WO2014116228A1 (en) 2013-01-25 2014-07-31 President And Fellows Of Harvard College Usp14 inhibitors for treating or preventing viral infections
WO2015073528A1 (en) * 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
CN103804270B (zh) * 2014-01-23 2016-06-22 中国药科大学 5-(4-甲脒基苄氧基)色氨酸衍生物、其制法及应用
WO2016144704A2 (en) * 2015-03-11 2016-09-15 Pharmakea, Inc. Heterocyclic autotaxin inhibitor compounds
US11795148B2 (en) 2017-12-12 2023-10-24 Queen's University At Kingston Compounds and methods for inhibiting CYP26 enzymes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB216847A (en) 1923-05-31 1925-02-12 Baptistin Branda Cylindrical steam distributor for direct action pumps
BE889929A (fr) 1980-08-12 1982-02-11 Glaxo Group Ltd Derives de l'indole, leur preparation et leurs utilisations therapeutiques
US4536505A (en) * 1983-05-17 1985-08-20 Ciba-Geigy Corporation Certain N-(pyridyl) indoles
GB8431426D0 (en) 1984-12-13 1985-01-23 Glaxo Group Ltd Chemical compounds
US5290936A (en) 1987-12-31 1994-03-01 London Diagnostics, Inc. Nitro substituted chemiluminescent labels and their conjugates, and assays therefrom
GB9317764D0 (en) * 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
US5902726A (en) 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
AU4400597A (en) * 1996-10-08 1998-05-05 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives
EP1140791A4 (en) 1997-09-23 2001-10-10 Bristol Myers Squibb Co SELECTIVE CPLA 2 INHIBITORS
ATE241615T1 (de) * 1998-03-09 2003-06-15 Lundbeck & Co As H 5-heteroaryl-substituierte indole
JPH11349568A (ja) 1998-06-08 1999-12-21 Maruho Co Ltd ラクタム誘導体及びその医薬用途
US6762200B2 (en) 2000-03-28 2004-07-13 Nippon Soda Co. Ltd. Oxa(thia)zolidine derivative and anti-inflammatory drug
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
EP1410822A4 (en) 2001-06-25 2007-06-20 Nippon Soda Co ZOLIDINE OXA (THIA) COMPOUNDS, PREPARATION PROCESS THEREFOR, AND ANTI-INFLAMMATORY AGENTS.
US20030236276A1 (en) 2001-08-06 2003-12-25 Ulrich Niewohner Pyrrolo[2.1-a]isoquinoline derivatives
ES2401454T3 (es) * 2001-12-03 2013-04-19 Wyeth Llc Inhibidores de la fosfolipasa A2 citosólica
EP2009064B1 (en) 2002-07-29 2012-10-24 Mitsubishi Paper Mills Limited Organic dye, photoelectric transducing material, semiconductor electrode, and photoelectric transducing device
AU2003254146A1 (en) 2003-07-24 2005-03-07 Case Western Reserve University Methods for the treatment of parkinson's disease
WO2006077366A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflammation
JP2008527027A (ja) 2005-01-19 2008-07-24 バイオリポックス エービー 炎症の治療に有用なインドール類
TW200718687A (en) 2005-05-27 2007-05-16 Wyeth Corp Inhibitors of cytosolic phospholipase A2

Also Published As

Publication number Publication date
MX2009010302A (es) 2009-10-16
CN101679248A (zh) 2010-03-24
WO2008120818A1 (ja) 2008-10-09
EP2141148A1 (en) 2010-01-06
RU2009139931A (ru) 2011-05-10
BRPI0809542A2 (pt) 2015-07-21
BRPI0809542A8 (pt) 2015-09-15
AU2008233553A1 (en) 2008-10-09
JP5164972B2 (ja) 2013-03-21
AU2008233553A2 (en) 2009-12-03
EP2141148B1 (en) 2013-07-03
EP2141148A4 (en) 2010-04-21
CA2681979A1 (en) 2008-10-09
KR20090125799A (ko) 2009-12-07
US8293781B2 (en) 2012-10-23
US20100113777A1 (en) 2010-05-06
JPWO2008120818A1 (ja) 2010-07-15

Similar Documents

Publication Publication Date Title
ES2422284T3 (es) Derivado de indol que tiene actividad inhibidora de cPLA2, uso del mismo y método para producirlo
SV2007002160A (es) Inhibidores de cetp ref. b.16744/shh
AR050932A1 (es) Amidas biciclicas como inhibidores de cinasa
CO6160322A2 (es) Derivados de quinazolinona e isoquinolinona acetamida
ECSP088824A (es) Prolinamidas sustituidas, su preparación y su uso como medicamentos
ECSP12012161A (es) Compuestos en calidad de antagonistas de Bradiquinina-b1
AR049443A1 (es) Derivados de pirrolpiridinas
PE20091381A1 (es) Inhibidores del virus de la hepatitis c
PE20091833A1 (es) Derivados heterociclicos espiro biciclicos o heterociclicos biciclicos, puenteados, de pirazolo [1,5-a]pirimidinas como inhibidores de quinasas raf y metodos para su preparacion
EA201000366A1 (ru) Производные 2-бифениламино-4-аминопиримидина в качестве ингибиторов киназ
PE20140625A1 (es) ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS
ECSP109978A (es) Nuevos compuestos
CR9069A (es) Derivados de indol tetraciclicos como agentes antiviricos
CY1113415T1 (el) Υποκατασταθεντα ν-φαινυλμεθυλ-5-οξο-προλιν-2-αμιδια ως ανταγωνιστες υποδοχεα ρ2χ7 και οι μεθοδοι χρησεως τους
UY32147A (es) Derivados de indol y de indolina y métodos para usarlos
AR053329A1 (es) Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
AR053301A1 (es) Derivados de pirazina y su uso farmaceutico
AR082343A2 (es) Un metodo de reduccion de desgaste por rozamiento para combustibles y procedimiento para preparar una composicion combustible
CY1115373T1 (el) Παραγωγο αμινοϊνδανιου ή αλας αυτου
AR036501A1 (es) Metodo para la sintesis de hexahidro-furo[2,3-b]furan-3-ol, e intermediarios
EA201070804A1 (ru) (аза)индольное производное, замещенное по положению 5, содержащая его фармацевтическая композиция, промежуточные соединения и способ их получения
ECSP10010105A (es) Antagonistas de cgrp
AR069436A1 (es) Compuestos de piridina
TW200637050A (en) OLED-device with patterned light emitting layer thickness
ECSP077306A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparación y su uso como antiinflamatorios